Humoral and Cellular Immune Responses Induced by Bivalent DNA Vaccines Expressing Fusion Capsid Proteins of Porcine Circovirus Genotypes 2a and 2b

Sochanwattey Meas,Khuanjit Chaimongkolnukul,Jaraspim Narkpuk,Phenjun Mekvichitsaeng,Kanokwan Poomputsa,Nanchaya Wanasen,Yaowaluck Maprang Roshorm

DOI: https://doi.org/10.3390/vaccines12030324

2024-03-19

Vaccines

Abstract:Porcine circovirus type 2 (PCV2) is the main causative agent of porcine circovirus-associated disease (PCVAD) that profoundly impacts the swine industry worldwide. While most of the commercial PCV vaccines are developed based on PCV genotype 2a (PCV2a), PCV genotype 2b (PCV2b) has become predominant since 2003. In this study, we developed and evaluated DNA-based bivalent vaccines covering both PCV2a and PCV2b. We generated a new immunogen, PCV2b-2a, by combining consensus sequences of the PCV2a and PCV2b capsid proteins (Cap2a and Cap2b) in a form of fusion protein. We also examined whether modifications of the PCV2b-2a fusion protein with a signal sequence (SS) and granulocyte macrophage-colony stimulating factor (GM-CSF) fusing with interleukine-4 (IL-4) (GI) could further improve the vaccine immunogenicity. An immunogenicity study of BALB/cAJcl mice revealed that the DNA vector pVAX1 co-expressing PCV2b-2a and GI (pVAX1.PCV2b-2a-GI) was most potent at inducing both antibody and cellular immune responses against Cap2a and Cap2b. Interestingly, the vaccines skewed the immune response towards Th1 phenotype (IgG2a > IgG1). By performing ELISA and ELISpot with predicted epitope peptides, the three most immunogenic B cell epitopes and five putative T cell epitopes were identified on Cap2a and Cap2b. Importantly, our DNA vaccines elicited broad immune responses recognizing both genotype-specific and PCV2-conserved epitopes. Sera from mice immunized with the DNAs expressing PCV2b-2a and PCV2b-2a-GI significantly inhibited PCV2a cell entry at serum dilution 1:8. All these results suggest a great potential of our PCV2b-2a-based vaccines, which can be further developed for use in other vaccine platforms to achieve both vaccine efficacy and economical production cost.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The main aim of this paper is to address the following issues:

1. **Development of a novel bivalent vaccine**: Given the prevalence of different genotypes of Porcine Circovirus Type 2 (PCV2), especially PCV2a and PCV2b, in pig populations worldwide and their impact on the swine industry, researchers have developed a novel bivalent DNA vaccine. This vaccine is capable of eliciting an immune response against both PCV2a and PCV2b genotypes.

2. **Enhancing vaccine immunogenicity**: To further enhance the immunogenicity of this bivalent vaccine, researchers explored the addition of signal peptide sequences (SS) and the fusion proteins GM-CSF and IL-4 (GI) to improve the vaccine's efficacy. These components are believed to promote the activation of antigen-presenting cells and enhance both humoral and cellular immune responses.

3. **Evaluating immune responses**: Through immunization experiments on BALB/cAJcl mice, the effectiveness of these improved vaccines in inducing antibody responses (including neutralizing antibodies) and cellular immune responses (such as the number of IFN-γ secreting cells) was evaluated, with particular attention to Th1-biased immune responses.

4. **Identifying immunodominant epitopes**: By predictive analysis and experimental validation, B-cell and T-cell epitopes on the capsid proteins of PCV2a and PCV2b were identified. This is crucial for understanding the mechanisms of immune responses and for future vaccine design.

In summary, the core objective of this study is to develop a novel bivalent DNA vaccine that can effectively prevent diseases caused by PCV2a and PCV2b, enhance its immunogenicity through various means, and ultimately achieve the goal of controlling PCV2 infections.